

Yun Ling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449394/publications.pdf>

Version: 2024-02-01

44
papers

5,655
citations

331538

21
h-index

254106

43
g-index

49
all docs

49
docs citations

49
times ranked

14370
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. <i>Radiology</i> , 2020, 295, 210-217.	3.6	997
2	Viral and host factors related to the clinical outcome of COVID-19. <i>Nature</i> , 2020, 583, 437-440.	13.7	746
3	COVID-19 with Different Severities: A Multicenter Study of Clinical Features. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1380-1388.	2.5	690
4	Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. <i>Chinese Medical Journal</i> , 2020, 133, 1039-1043.	0.9	686
5	Clinical progression of patients with COVID-19 in Shanghai, China. <i>Journal of Infection</i> , 2020, 80, e1-e6.	1.7	627
6	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
7	Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. <i>Journal of Experimental Medicine</i> , 2015, 212, 619-631.	4.2	162
8	Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. <i>EMBO Journal</i> , 2020, 39, e105896.	3.5	123
9	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa241.	0.4	97
10	Pre-optimized phage therapy on secondary <i>Acinetobacter baumannii</i> infection in four critical COVID-19 patients. <i>Emerging Microbes and Infections</i> , 2021, 10, 612-618.	3.0	80
11	Mitochondrial Sirtuin 4 Resolves Immune Tolerance in Monocytes by Rebalancing Glycolysis and Glucose Oxidation Homeostasis. <i>Frontiers in Immunology</i> , 2018, 9, 419.	2.2	69
12	Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. <i>Phytomedicine</i> , 2021, 85, 153390.	2.3	60
13	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. <i>Emerging Microbes and Infections</i> , 2020, 9, 1988-1996.	3.0	58
14	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. <i>Frontiers of Medicine</i> , 2020, 14, 746-751.	1.5	57
15	Clinical Potential of ¹ UTE-MRI for Assessing COVID-19: Patient- and Lesion-Based Comparative Analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 397-406.	1.9	48
16	An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1518-1523.	3.0	42
17	Integrated analysis of gut microbiome and host immune responses in COVID-19. <i>Frontiers of Medicine</i> , 2022, 16, 263-275.	1.5	35
18	An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis. <i>Cytokine</i> , 2021, 138, 155365.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 625881.	2.2	30
20	Observations about symptomatic and asymptomatic infections of 494 patients with COVID-19 in Shanghai, China. <i>American Journal of Infection Control</i> , 2020, 48, 1045-1050.	1.1	28
21	Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. <i>Cell Discovery</i> , 2021, 7, 89.	3.1	27
22	Switch of NAD Salvage to de novo Biosynthesis Sustains SIRT1-RelB-Dependent Inflammatory Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 2358.	2.2	25
23	Dynamic anti-spike protein antibody profiles in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 103, 540-548.	1.5	25
24	A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. <i>Infection</i> , 2020, 48, 577-584.	2.3	25
25	Epidemiology and clinical course of COVID-19 in Shanghai, China. <i>Emerging Microbes and Infections</i> , 2020, 9, 1537-1545.	3.0	24
26	Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 196, 113927.	1.4	23
27	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
28	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- β plus TFF2 in patients with moderate COVID-19. <i>EclinicalMedicine</i> , 2020, 25, 100478.	3.2	20
29	Application of ordinal logistic regression analysis to identify the determinants of illness severity of COVID-19 in China. <i>Epidemiology and Infection</i> , 2020, 148, e146.	1.0	20
30	The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa286.	0.4	19
31	Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 568-580.	1.9	17
32	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. <i>Scientific Reports</i> , 2021, 11, 4405.	1.6	15
33	Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 91.	7.1	14
34	Co-infection in COVID-19, a cohort study. <i>Journal of Infection</i> , 2021, 82, 414-451.	1.7	11
35	Genetic and Clinical Profiles of Disseminated <i>Bacillus Calmette-Guérin</i> Disease and Chronic Granulomatous Disease in China. <i>Frontiers in Immunology</i> , 2019, 10, 73.	2.2	10
36	Analysis of risk factors of PICC-related bloodstream infection in newborns: implications for nursing care. <i>European Journal of Medical Research</i> , 2021, 26, 80.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. <i>BioScience Trends</i> , 2020, 14, 161-167.	1.1	8
38	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 287-298.	1.6	5
39	Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient. <i>Diagnostic Pathology</i> , 2021, 16, 40.	0.9	3
40	Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, China. <i>Australasian Journal on Ageing</i> , 2021, , .	0.4	3
41	Immune profiles of a COVID-19 adolescent with mild symptoms and anti-viral antibody deficiency. <i>Fundamental Research</i> , 2021, 1, 117-123.	1.6	2
42	Clinical Immunophenotype at Disease Onset in Previously Healthy Patients With Cryptococcal Meningitis. <i>Medicine (United States)</i> , 2016, 95, e2744.	0.4	1
43	“浙大” 新型冠状病毒肺炎临床特征分析. <i>浙江大學學報(醫學版)</i> = <i>Journal of Zhejiang University (Medical Science)</i>		
44	Preliminary investigation of relationship between clinical indicators and CT manifestation patterns of COVID-19 pneumonia improvement. <i>Journal of Thoracic Disease</i> , 2020, 12, 5896-5905.	0.6	0